BidaskClub upgraded shares of Progenics Pharmaceuticals (NASDAQ:PGNX) from a sell rating to a hold rating in a research note published on Wednesday.
Other analysts also recently issued reports about the company. Cantor Fitzgerald reaffirmed a buy rating and set a $15.00 price objective on shares of Progenics Pharmaceuticals in a research note on Wednesday, January 17th. ValuEngine raised Progenics Pharmaceuticals from a sell rating to a hold rating in a research note on Thursday, December 7th. Finally, Zacks Investment Research downgraded Progenics Pharmaceuticals from a buy rating to a hold rating in a research note on Saturday, January 6th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of Buy and a consensus price target of $12.35.
Shares of Progenics Pharmaceuticals (NASDAQ PGNX) opened at $5.97 on Wednesday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 7.86 and a current ratio of 7.86. The company has a market capitalization of $406.86, a P/E ratio of -7.56 and a beta of 3.41. Progenics Pharmaceuticals has a one year low of $4.60 and a one year high of $11.72.
ILLEGAL ACTIVITY NOTICE: “Progenics Pharmaceuticals (PGNX) Upgraded at BidaskClub” was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://stocknewstimes.com/2018/02/17/progenics-pharmaceuticals-pgnx-upgraded-at-bidaskclub.html.
About Progenics Pharmaceuticals
Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.
Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.